GlaxoSmithKline’s (NYSE:GSK) Neutral Rating Reaffirmed at JPMorgan Chase & Co.

GlaxoSmithKline (NYSE:GSK)‘s stock had its “neutral” rating reiterated by equities researchers at JPMorgan Chase & Co. in a report issued on Thursday, January 11th.

Other equities analysts have also recently issued research reports about the company. Zacks Investment Research cut GlaxoSmithKline from a “buy” rating to a “hold” rating in a report on Wednesday, January 10th. Investec cut GlaxoSmithKline from a “buy” rating to a “hold” rating in a report on Monday, November 6th. Bank of America cut GlaxoSmithKline from a “buy” rating to a “neutral” rating in a report on Thursday, October 26th. TheStreet upgraded GlaxoSmithKline from a “c+” rating to a “b” rating in a report on Wednesday, October 25th. Finally, Argus dropped their target price on GlaxoSmithKline to $40.00 and set a “buy” rating for the company in a report on Thursday, November 30th. Three equities research analysts have rated the stock with a sell rating, ten have given a hold rating and six have given a buy rating to the company. The stock currently has an average rating of “Hold” and an average target price of $38.57.

GlaxoSmithKline (GSK) opened at $38.15 on Thursday. The company has a market capitalization of $94,002.70, a P/E ratio of 31.27, a PEG ratio of 2.17 and a beta of 0.98. The company has a quick ratio of 0.44, a current ratio of 0.64 and a debt-to-equity ratio of 2.96. GlaxoSmithKline has a 1-year low of $34.52 and a 1-year high of $44.53.

GlaxoSmithKline (NYSE:GSK) last announced its earnings results on Wednesday, October 25th. The pharmaceutical company reported $0.85 EPS for the quarter, topping the Zacks’ consensus estimate of $0.84 by $0.01. GlaxoSmithKline had a return on equity of 115.30% and a net margin of 7.79%. research analysts forecast that GlaxoSmithKline will post 2.9 earnings per share for the current year.

In other GlaxoSmithKline news, major shareholder Plc Glaxosmithkline acquired 428,571 shares of the company’s stock in a transaction that occurred on Monday, November 6th. The stock was bought at an average price of $14.00 per share, for a total transaction of $5,999,994.00. The transaction was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. 10.00% of the stock is owned by insiders.

A number of hedge funds and other institutional investors have recently modified their holdings of the business. 1st Global Advisors Inc. raised its position in GlaxoSmithKline by 0.4% during the 2nd quarter. 1st Global Advisors Inc. now owns 5,271 shares of the pharmaceutical company’s stock valued at $227,000 after purchasing an additional 19 shares in the last quarter. King Luther Capital Management Corp raised its position in GlaxoSmithKline by 1.0% during the 2nd quarter. King Luther Capital Management Corp now owns 5,432 shares of the pharmaceutical company’s stock valued at $234,000 after purchasing an additional 55 shares in the last quarter. Strategic Global Advisors LLC raised its position in GlaxoSmithKline by 0.6% during the 2nd quarter. Strategic Global Advisors LLC now owns 12,179 shares of the pharmaceutical company’s stock valued at $525,000 after purchasing an additional 75 shares in the last quarter. PagnatoKarp Partners LLC raised its position in GlaxoSmithKline by 1.4% during the 2nd quarter. PagnatoKarp Partners LLC now owns 5,812 shares of the pharmaceutical company’s stock valued at $253,000 after purchasing an additional 80 shares in the last quarter. Finally, Peapack Gladstone Financial Corp raised its position in GlaxoSmithKline by 1.0% during the 2nd quarter. Peapack Gladstone Financial Corp now owns 11,740 shares of the pharmaceutical company’s stock valued at $506,000 after purchasing an additional 115 shares in the last quarter. 9.80% of the stock is owned by institutional investors and hedge funds.

ILLEGAL ACTIVITY NOTICE: This piece was posted by The Ledger Gazette and is owned by of The Ledger Gazette. If you are reading this piece on another site, it was stolen and reposted in violation of U.S. and international copyright & trademark legislation. The legal version of this piece can be read at https://ledgergazette.com/2018/01/18/glaxosmithkline-gsk-rating-reiterated-by-jpmorgan-chase-co.html.

GlaxoSmithKline Company Profile

GlaxoSmithKline plc is a global healthcare company. The Company operates through three segments: Pharmaceuticals, Vaccines and Consumer Healthcare. The Company focuses on its research across six areas: Respiratory diseases, human immunodeficiency virus (HIV)/infectious diseases, Vaccines, Immuno-inflammation, Oncology and Rare diseases.

Analyst Recommendations for GlaxoSmithKline (NYSE:GSK)

Receive News & Ratings for GlaxoSmithKline Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GlaxoSmithKline and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply